Test helps identify candidates for new bladder cancer agent
Laboratory Corp. of America Holding (LabCorp) has made available VENTANA PD-L1 (SP142) Assay as a complementary diagnostic test in the treatment of urothelial cancer. Designed to be used in conjunction with atezolizumab (TECENTRIQ), which was recently FDA approved for the treatment of certain individuals with locally advanced or metastatic urothelial carcinoma, VENTANA PD-L1 Assay will help identify patients who may benefit from atezolizumab treatment. The test was developed by Roche Diagnostics. It can identify the PD-L1 protein on tumor infiltrating immune cells and will also provide physicians with an immune cell scoring algorithm. VENTANA PD-L1 Assay was approved by the FDA in May 2016.
For more information, visit www.labcorp.com.